5 Minutes Read

WHO classifies new variant as ‘highly transmissible’ virus, names it omicron

KV Prasad Jun 13, 2022, 06:35 AM IST (Published)

 Listen to the Article (6 Minutes)

Summary

The World Health Organisation classified a new COVID-19 variant first detected in South Africa as a highly transmissible virus of concern and named it omicron under its Greek-letter system.

An advisory panel of the World Health Organisation classified a new COVID-19 variant first detected in South Africa as a highly transmissible virus of concern and named it omicron under its Greek-letter system.

Elon Musk forms several ‘X Holdings’ companies to fund potential Twitter buyout

3 Mins Read

Thursday’s filing dispelled some doubts, though Musk still has work to do. He and his advisers will spend the coming days vetting potential investors for the equity portion of his offer, according to people familiar with the matter

 Daily Newsletter

KV Prasad Journo follow politics, process in Parliament and US Congress. Former Congressional APSA-Fulbright Fellow

Previous Article

Oil Fluctuates as Traders Assess China’s Vow, Unrest in Libya

Next Article

Shanghai residents turn to NFTs to record COVID lockdown, combat censorship

LIVE TV

today's market

index Price Change
nifty 50 ₹16,986.00 -72.15
sensex ₹1,882.60 +28.30
nifty IT ₹2,206.80 +30.85
nifty bank ₹1,318.95 -14.95
index Price Change
nifty 50 ₹16,986.00 -7.15
sensex ₹1,882.60 +8.30
nifty IT ₹2,206.80 +3.85
nifty bank ₹1,318.95 -1.95
index Price Change
nifty 50 ₹16,986.00 -72.15
sensex ₹1,882.60 +28.30
nifty IT ₹2,206.80 +30.85
nifty bank ₹1,318.95 -14.95
index Price Change
nifty 50 ₹16,986.00 -7.15
sensex ₹1,882.60 +8.30
nifty IT ₹2,206.80 +3.85
nifty bank ₹1,318.95 -1.95
index Price Change
nifty 50 ₹16,986.00 -7.15
sensex ₹1,882.60 +8.30
nifty IT ₹2,206.80 +3.85
nifty bank ₹1,318.95 -1.95

Currency

Company Price Chng %Chng
Dollar-Rupee 73.3500 0.0000 0.00
Euro-Rupee 89.0980 0.0100 0.01
Pound-Rupee 103.6360 -0.0750 -0.07
Rupee-100 Yen 0.6734 -0.0003 -0.05
Quiz
Powered by
Are you a Crypto Head? It’s time to prove it!
10 Questions · 5 Minutes
Start Quiz Now
Win WRX (WazirX token) worth Rs. 1500.
Question 1 of 5

What coins do you think will be valuable over next 3 years?

Answer Anonymously

Should Elon Musk be able to buy Twitter?

 5 Minutes Read

All you need to know about COVID-19 variant C.1.2; it mutates the fastest

KV Prasad Jun 13, 2022, 06:35 AM IST (Published)

 Listen to the Article (6 Minutes)

Summary

C.1.2 was first detected in South Africa in May 2021. It has also been found in China, the Democratic Republic of the Congo, Mauritius, England, New Zealand, Portugal and Switzerland. Not a single case in India, so far.

The C.1.2 strain, which was discovered in South Africa in May this year, could spread faster than the existing virus as it is capable of making 41.8 mutations per year, which is approximately 1.7-fold faster than the current global rate, experts have warned. The strain has spread to other countries, but India has not yet reported a single case caused by this strain.

What is this variant?

The C.1.2 variant — which was first detected in South Africa in May this year — has evolved from C.1, which is one of the lineages that dominated the first wave of SARS-CoV-2 infections in South Africa.

Which countries have detected it so far?

Scientists from the National Institute for Communicable Diseases (NICD) and the KwaZulu-Natal Research Innovation and Sequencing Platform (KRISP) in South Africa said the potential variant of interest (VoI), C.1.2, was first detected in the country in May this year in the Mpumalanga and Gauteng provinces. It has now spread across the majority of the provinces in South Africa. The C.1.2 has also been found in China, the Democratic Republic of the Congo, Mauritius, England, New Zealand, Portugal and Switzerland.

The research is yet to be peer reviewed and currently remains posted on pre-print server medRxiv.

How deadly is this new strain?

The C.1.2 is quite deadly compared to the earlier versions. It is associated with increased transmissibility and reduced neutralisation sensitivity. One researcher said the new variant has “mutated substantially” and it is way ahead of the original virus initially detected in Wuhan. It is believed this virus is even way ahead of any other variant of concern (VoC) or VoI detected so far worldwide.

How fast is this mutating?

The C.1.2 can have 41.8 mutations every year, as per a study. That is approximately 1.7-fold faster than the current global rate and 1.8-fold faster than the initial estimate of SARS-CoV-2 evolution. Scientists say that other viruses such as Alpha, Beta, and Gamma VoCs underwent a similarly short period of evolution.

Also read: COVID-19 Delta variant is driving infections in India; all you need to know

What are the symptoms?

Experts are yet to ascertain what could be the new symptoms but the common symptoms across all COVID-19 variants are runny nose, persistent cough, throat pain, body ache, loss of smell and taste, fever, muscle cramps, pink eyes, diarrhoea, etc.

Has it spread to India?

India has not detected the C.1.2 variant till date. It has detected a new sub-lineage AY.12 of the Delta variant though that was recently classified in Israel. As per a recent report by the Indian SARS-CoV-2 Genomics Consortium (INSACOG), many cases that were classified as Delta are now being reclassified as AY.12.

Also read: India may be in endemic stage of COVID-19, says WHO expert; what that means

Elon Musk forms several ‘X Holdings’ companies to fund potential Twitter buyout

3 Mins Read

Thursday’s filing dispelled some doubts, though Musk still has work to do. He and his advisers will spend the coming days vetting potential investors for the equity portion of his offer, according to people familiar with the matter

 Daily Newsletter

KV Prasad Journo follow politics, process in Parliament and US Congress. Former Congressional APSA-Fulbright Fellow

Previous Article

Oil Fluctuates as Traders Assess China’s Vow, Unrest in Libya

Next Article

Shanghai residents turn to NFTs to record COVID lockdown, combat censorship

LIVE TV

today's market

index Price Change
nifty 50 ₹16,986.00 -72.15
sensex ₹1,882.60 +28.30
nifty IT ₹2,206.80 +30.85
nifty bank ₹1,318.95 -14.95
index Price Change
nifty 50 ₹16,986.00 -7.15
sensex ₹1,882.60 +8.30
nifty IT ₹2,206.80 +3.85
nifty bank ₹1,318.95 -1.95
index Price Change
nifty 50 ₹16,986.00 -72.15
sensex ₹1,882.60 +28.30
nifty IT ₹2,206.80 +30.85
nifty bank ₹1,318.95 -14.95
index Price Change
nifty 50 ₹16,986.00 -7.15
sensex ₹1,882.60 +8.30
nifty IT ₹2,206.80 +3.85
nifty bank ₹1,318.95 -1.95
index Price Change
nifty 50 ₹16,986.00 -7.15
sensex ₹1,882.60 +8.30
nifty IT ₹2,206.80 +3.85
nifty bank ₹1,318.95 -1.95

Currency

Company Price Chng %Chng
Dollar-Rupee 73.3500 0.0000 0.00
Euro-Rupee 89.0980 0.0100 0.01
Pound-Rupee 103.6360 -0.0750 -0.07
Rupee-100 Yen 0.6734 -0.0003 -0.05
Quiz
Powered by
Are you a Crypto Head? It’s time to prove it!
10 Questions · 5 Minutes
Start Quiz Now
Win WRX (WazirX token) worth Rs. 1500.
Question 1 of 5

What coins do you think will be valuable over next 3 years?

Answer Anonymously

Should Elon Musk be able to buy Twitter?

 5 Minutes Read

West Africa reports death from Ebola-like Marburg virus; all you need to know

KV Prasad Jun 13, 2022, 06:35 AM IST (Published)

 Listen to the Article (6 Minutes)

Summary

The virus is highly infectious and is carried by bats. It has a fatality rate of up to 88 percent. It shares its name with the German town of Marburg, where an outbreak occurred in 1967.

Guinea in western Africa has confirmed a case of Marburg disease. The Marburg virus causes haemorrhagic fever and belongs to the same family as the Ebola virus. The World Health Organization (WHO) said on August 9 that the virus, which is carried by bats and has a fatality rate of up to 88 percent, was found in samples taken from a patient who died on August 2 in southern Gueckedou prefecture.

The case was discovered just two months after the WHO announced the end of the country’s second Ebola outbreak.

Dr Matshidiso Moeti, WHO Regional Director for Africa, told the media, “The potential for the Marburg virus to spread far and wide means we need to stop it in its tracks. We are working with the health authorities to implement a swift response that builds on Guinea’s past experience with Ebola, which is transmitted in a similar way.”

Here’s all you need to know about this deadly virus:

  1. The World Health Organization says this disease is caused by a virus that comes from the same family (filoviridae or filovirus) of virus that causes Ebola.
  2. The common symptoms of this disease include haemorrhagic fever, muscle aches, severe headaches, diarrhoea, abdominal pain, cramping, nausea and vomiting.
  3. The Marburg virus shares its name with the German town of Marburg where an outbreak occurred in 1967. Other cities like Frankfurt, Belgrade, and present-day Serbia also witnessed Marburg outbreaks in the same year.
  4. Human beings can catch this deadly infection through prolonged exposure to mines or caves inhabited by Rousettus bats. Once someone comes in contact with this virus, it can be transmitted through direct contact with blood, secretions, bodily fluids of infected individuals and also via surfaces and materials contaminated with such fluids.
  5. The WHO and the US Centers for Disease Control and Prevention (CDC) have said that there is no approved vaccine or antiviral drug for this disease. As of now, only supportive care therapy and rehydration with oral fluids can be helpful.
  6. WHO says the fatality rate has ranged from 24-88 percent in previous outbreaks depending upon the virus strain and case management.
  7. Previously, the cases of this virus in Africa have been reported from Angola, Democratic Republic of Congo, South Africa, Kenya, and Uganda.

Elon Musk forms several ‘X Holdings’ companies to fund potential Twitter buyout

3 Mins Read

Thursday’s filing dispelled some doubts, though Musk still has work to do. He and his advisers will spend the coming days vetting potential investors for the equity portion of his offer, according to people familiar with the matter

 Daily Newsletter

KV Prasad Journo follow politics, process in Parliament and US Congress. Former Congressional APSA-Fulbright Fellow

Previous Article

Oil Fluctuates as Traders Assess China’s Vow, Unrest in Libya

Next Article

Shanghai residents turn to NFTs to record COVID lockdown, combat censorship

LIVE TV

today's market

index Price Change
nifty 50 ₹16,986.00 -72.15
sensex ₹1,882.60 +28.30
nifty IT ₹2,206.80 +30.85
nifty bank ₹1,318.95 -14.95
index Price Change
nifty 50 ₹16,986.00 -7.15
sensex ₹1,882.60 +8.30
nifty IT ₹2,206.80 +3.85
nifty bank ₹1,318.95 -1.95
index Price Change
nifty 50 ₹16,986.00 -72.15
sensex ₹1,882.60 +28.30
nifty IT ₹2,206.80 +30.85
nifty bank ₹1,318.95 -14.95
index Price Change
nifty 50 ₹16,986.00 -7.15
sensex ₹1,882.60 +8.30
nifty IT ₹2,206.80 +3.85
nifty bank ₹1,318.95 -1.95
index Price Change
nifty 50 ₹16,986.00 -7.15
sensex ₹1,882.60 +8.30
nifty IT ₹2,206.80 +3.85
nifty bank ₹1,318.95 -1.95

Currency

Company Price Chng %Chng
Dollar-Rupee 73.3500 0.0000 0.00
Euro-Rupee 89.0980 0.0100 0.01
Pound-Rupee 103.6360 -0.0750 -0.07
Rupee-100 Yen 0.6734 -0.0003 -0.05
Quiz
Powered by
Are you a Crypto Head? It’s time to prove it!
10 Questions · 5 Minutes
Start Quiz Now
Win WRX (WazirX token) worth Rs. 1500.
Question 1 of 5

What coins do you think will be valuable over next 3 years?

Answer Anonymously

Should Elon Musk be able to buy Twitter?

 5 Minutes Read

COVID-19: Triple mutation strain of virus raises concern, says report

KV Prasad Jun 13, 2022, 06:35 AM IST (Published)

 Listen to the Article (6 Minutes)

Summary

The triple mutation follows the double mutation which means three different COVID strains have combined to form a novel variant.

As India recorded about three lakh cases and over 2,000 deaths in the last 24 hours due to the COVID-19 infections, a new mutation variant in the COVID-19 virus has been detected in parts of the country, becoming the cause of fresh concerns, NDTV report suggests.

The triple mutation follows the double mutation which means three different COVID strains have combined to form a novel variant. States of Maharashtra, Delhi and West Bengal are believed to have cases driven by this new COVID mutant, the report mentioned.

The new spikes in COVID-19 cases across the globe are driven by new variants according to some scientists.

“This is a more transmissible variant. It is making lots of people sick very quickly,” reported NDTV quoting Madhukar Pai, professor of epidemiology at McGill University. Professor Pai also stressed on the need to “keep tweaking the vaccine” and the “sequencing on war footing”. He also added that the delay in detecting the double mutation may have contributed to the current virus spurt.

The recent mutant poses a massive challenge for India, where genome sequencing is being done for less than one percent of all cases currently, the NDTV report mentioned.

The science behind mutations is that the more a virus spreads the more it replicates and the more it mutates.

More studies are required to establish how infectious or deadly the triple mutation can prove to be, for now, only 10 labs across India are involved in virus genome studies, the report added. The double mutant has resulted in increased transmission rate and is seen to impact children too with more severe pathogenicity, according to scientists.

Currently, the triple mutation has been classified in India as a “variant of interest” rather than a “variant of concern”, according to the report.

Will existing vaccines be effective against the new mutant?

Two of the three variants in the triple mutation are more resistant to antibodies and not much is known yet on the effectiveness of vaccines. Scientists do believe the new variant contains the ability to escape the body’s naturally acquired immunity to COVID-19, according to the report.

Elon Musk forms several ‘X Holdings’ companies to fund potential Twitter buyout

3 Mins Read

Thursday’s filing dispelled some doubts, though Musk still has work to do. He and his advisers will spend the coming days vetting potential investors for the equity portion of his offer, according to people familiar with the matter

 Daily Newsletter

KV Prasad Journo follow politics, process in Parliament and US Congress. Former Congressional APSA-Fulbright Fellow

Previous Article

Oil Fluctuates as Traders Assess China’s Vow, Unrest in Libya

Next Article

Shanghai residents turn to NFTs to record COVID lockdown, combat censorship

LIVE TV

today's market

index Price Change
nifty 50 ₹16,986.00 -72.15
sensex ₹1,882.60 +28.30
nifty IT ₹2,206.80 +30.85
nifty bank ₹1,318.95 -14.95
index Price Change
nifty 50 ₹16,986.00 -7.15
sensex ₹1,882.60 +8.30
nifty IT ₹2,206.80 +3.85
nifty bank ₹1,318.95 -1.95
index Price Change
nifty 50 ₹16,986.00 -72.15
sensex ₹1,882.60 +28.30
nifty IT ₹2,206.80 +30.85
nifty bank ₹1,318.95 -14.95
index Price Change
nifty 50 ₹16,986.00 -7.15
sensex ₹1,882.60 +8.30
nifty IT ₹2,206.80 +3.85
nifty bank ₹1,318.95 -1.95
index Price Change
nifty 50 ₹16,986.00 -7.15
sensex ₹1,882.60 +8.30
nifty IT ₹2,206.80 +3.85
nifty bank ₹1,318.95 -1.95

Currency

Company Price Chng %Chng
Dollar-Rupee 73.3500 0.0000 0.00
Euro-Rupee 89.0980 0.0100 0.01
Pound-Rupee 103.6360 -0.0750 -0.07
Rupee-100 Yen 0.6734 -0.0003 -0.05
Quiz
Powered by
Are you a Crypto Head? It’s time to prove it!
10 Questions · 5 Minutes
Start Quiz Now
Win WRX (WazirX token) worth Rs. 1500.
Question 1 of 5

What coins do you think will be valuable over next 3 years?

Answer Anonymously

Should Elon Musk be able to buy Twitter?

 5 Minutes Read

Explained: Will latest lockdowns, curbs derail GDP recovery worldwide?

KV Prasad Jun 13, 2022, 06:35 AM IST (Published)

 Listen to the Article (6 Minutes)

Summary

Markets and economies are navigating a sequence of vaccine optimism and virus risks, with the mutant strain too now thrown in the equation. Let us take a look at where we stand in India and around the world, and how things stacked are.

Markets and economies are navigating a sequence of vaccine optimism and virus risks, with the mutant strain too now thrown in the equation. Let us take a look at where we stand in India and around the world, and how things stacked are.

The re-opening narrative has encountered a reality check over the past couple of weeks. A surge in the number of COVID-19 cases is a reminder that we are not out of the woods yet. Immediate virus risks means that more lockdowns are likely, especially into Easter for Europe and Latin America.

For Europe, the lockdowns represent a brake on the economic recovery. For emerging markets (EM) countries, India included, the big worry is that COVID-19 will exacerbate macroeconomic challenges such as fiscal pressures. The divergence in the pace of vaccination remains a differentiating factor for markets. The US and China are the main pillars of the world economy, and of these two, the US appears to be better poised on the track to growth.

Watch this video for more.

Elon Musk forms several ‘X Holdings’ companies to fund potential Twitter buyout

3 Mins Read

Thursday’s filing dispelled some doubts, though Musk still has work to do. He and his advisers will spend the coming days vetting potential investors for the equity portion of his offer, according to people familiar with the matter

 Daily Newsletter

KV Prasad Journo follow politics, process in Parliament and US Congress. Former Congressional APSA-Fulbright Fellow

Previous Article

Oil Fluctuates as Traders Assess China’s Vow, Unrest in Libya

Next Article

Shanghai residents turn to NFTs to record COVID lockdown, combat censorship

LIVE TV

today's market

index Price Change
nifty 50 ₹16,986.00 -72.15
sensex ₹1,882.60 +28.30
nifty IT ₹2,206.80 +30.85
nifty bank ₹1,318.95 -14.95
index Price Change
nifty 50 ₹16,986.00 -7.15
sensex ₹1,882.60 +8.30
nifty IT ₹2,206.80 +3.85
nifty bank ₹1,318.95 -1.95
index Price Change
nifty 50 ₹16,986.00 -72.15
sensex ₹1,882.60 +28.30
nifty IT ₹2,206.80 +30.85
nifty bank ₹1,318.95 -14.95
index Price Change
nifty 50 ₹16,986.00 -7.15
sensex ₹1,882.60 +8.30
nifty IT ₹2,206.80 +3.85
nifty bank ₹1,318.95 -1.95
index Price Change
nifty 50 ₹16,986.00 -7.15
sensex ₹1,882.60 +8.30
nifty IT ₹2,206.80 +3.85
nifty bank ₹1,318.95 -1.95

Currency

Company Price Chng %Chng
Dollar-Rupee 73.3500 0.0000 0.00
Euro-Rupee 89.0980 0.0100 0.01
Pound-Rupee 103.6360 -0.0750 -0.07
Rupee-100 Yen 0.6734 -0.0003 -0.05
Quiz
Powered by
Are you a Crypto Head? It’s time to prove it!
10 Questions · 5 Minutes
Start Quiz Now
Win WRX (WazirX token) worth Rs. 1500.
Question 1 of 5

What coins do you think will be valuable over next 3 years?

Answer Anonymously

Should Elon Musk be able to buy Twitter?

 5 Minutes Read

Cabin air purification tech to inhibit viruses, bacteria by up to 97% : JLR

KV Prasad Jun 13, 2022, 06:35 AM IST (Published)

 Listen to the Article (6 Minutes)

Summary

”The independent research, developed and commissioned by our expert engineers, is just one of the ways we are working to assure our customers that harmful pathogens are being minimised, providing a cleaner environment for passengers inside the cabin and setting new standards in the ownership experience,” JLR Chief Medical Officer Steve Iley noted.

Jaguar Land Rover (JLR) on Tuesday said its under-development cabin air purification technology has shown the ability to inhibit viruses and airborne bacteria by as much as 97 percent in the laboratory tests. The prototype heating, ventilation, and air conditioning (HVAC) system uses Panasonic’s technology to inhibit harmful bacteria and viruses and will help the cabins of future Jaguar and Land Rover models to deliver a unique customer experience, Tata Motors’ owned luxury carmaker said in a statement.

The research comes as the company defines its future strategy: a sustainability-rich reimagination of modern luxury, unique customer experiences, and positive societal impact, it added. JLR said it has partnered with Perfectus Biomed Ltd, a leading microbiology and virology lab, to perform the laboratory-based sealed-chamber test designed to simulate a vehicle ventilation system in recirculation mode over a 30-minute cycle.

The independent research showed that viruses and bacteria were inhibited by as much as 97 percent, it added. Our customers’ well-being is of paramount importance to us and now, more than ever, we are all looking for technological solutions that can help take care of our loved ones.

”The independent research, developed and commissioned by our expert engineers, is just one of the ways we are working to assure our customers that harmful pathogens are being minimised, providing a cleaner environment for passengers inside the cabin and setting new standards in the ownership experience,” JLR Chief Medical Officer Steve Iley noted. The ongoing research will allow the automaker to offer the next generation of advanced cabin air filtration in the future, he added.

”This technology is a great example of being able to harness the power of nature and puts Jaguar Land Rover right at the forefront of this cabin technology. Hydroxyl Radicals are one of the most important natural oxidants in chemistry and have been helping to clean our atmosphere for millennia, removing pollutants and other harmful substances,” JLR Research Engineer Alexander Owen said.

Currently, models across the Jaguar range, including the new all-electric I-PACE performance SUV, and Land Rover line-up including the Discovery and Range Rover Evoque offer nanoe technology and PM 2.5 filtration.

Elon Musk forms several ‘X Holdings’ companies to fund potential Twitter buyout

3 Mins Read

Thursday’s filing dispelled some doubts, though Musk still has work to do. He and his advisers will spend the coming days vetting potential investors for the equity portion of his offer, according to people familiar with the matter

 Daily Newsletter

KV Prasad Journo follow politics, process in Parliament and US Congress. Former Congressional APSA-Fulbright Fellow

Previous Article

Oil Fluctuates as Traders Assess China’s Vow, Unrest in Libya

Next Article

Shanghai residents turn to NFTs to record COVID lockdown, combat censorship

LIVE TV

today's market

index Price Change
nifty 50 ₹16,986.00 -72.15
sensex ₹1,882.60 +28.30
nifty IT ₹2,206.80 +30.85
nifty bank ₹1,318.95 -14.95
index Price Change
nifty 50 ₹16,986.00 -7.15
sensex ₹1,882.60 +8.30
nifty IT ₹2,206.80 +3.85
nifty bank ₹1,318.95 -1.95
index Price Change
nifty 50 ₹16,986.00 -72.15
sensex ₹1,882.60 +28.30
nifty IT ₹2,206.80 +30.85
nifty bank ₹1,318.95 -14.95
index Price Change
nifty 50 ₹16,986.00 -7.15
sensex ₹1,882.60 +8.30
nifty IT ₹2,206.80 +3.85
nifty bank ₹1,318.95 -1.95
index Price Change
nifty 50 ₹16,986.00 -7.15
sensex ₹1,882.60 +8.30
nifty IT ₹2,206.80 +3.85
nifty bank ₹1,318.95 -1.95

Currency

Company Price Chng %Chng
Dollar-Rupee 73.3500 0.0000 0.00
Euro-Rupee 89.0980 0.0100 0.01
Pound-Rupee 103.6360 -0.0750 -0.07
Rupee-100 Yen 0.6734 -0.0003 -0.05
Quiz
Powered by
Are you a Crypto Head? It’s time to prove it!
10 Questions · 5 Minutes
Start Quiz Now
Win WRX (WazirX token) worth Rs. 1500.
Question 1 of 5

What coins do you think will be valuable over next 3 years?

Answer Anonymously

Should Elon Musk be able to buy Twitter?

 5 Minutes Read

Bird flu in India: Can I eat eggs or chicken? All you need to know

KV Prasad Jun 13, 2022, 06:35 AM IST (Published)

 Listen to the Article (6 Minutes)

Summary

Thousands of chickens and ducks were culled in two districts of Kerala to contain the spread of the H5N8 avian influenza strain

A high alert has been sounded in several states following the outbreak of bird flu and the Centre has deployed multi-disciplinary teams in affected areas. There have been a lot of questions on whether one should consume poultry products or not, what precautionary measures should be taken, what are the symptoms when one contracts avian influenza, what’s the treatment etc.

India had notified the first outbreak of avian influenza in 2006. The current outbreak has been reported a few months after India declared the country free from the disease on September 30, 2020.

Over the past few days, thousands of chickens and ducks have been culled in two districts in Kerala to contain the spread of the H5N8 avian influenza strain and Rajasthan reported that bird flu was detected in Swai Madhopur, after Jhalawar, Kota, Baran, and Jaipur districts recently.

Here are answers to a few questions on the deadly avian influenza according to the All India Institute of Medical Sciences (AIIMS).

1. What is avian influenza?

Avian influenza or bird flu is an infection caused by avian (bird) influenza (flu) viruses. These viruses occur naturally among birds. Wild birds carry these viruses in their intestines, but they usually do not get sick from them. It is highly contagious among birds and can prove fatal for domesticated birds, including chickens and ducks.

2. Should one consume poultry and poultry products?

Yes, poultry and poultry products can be prepared and consumed without any fear of contracting an infection. But one must practice good hygiene. The virus is destroyed at a temperature of 70 degrees Celsius for 30 minutes. One must wash hands with soap after handling poultry products.

3. Should one use chicken-droppings as manure?

It is advised not to come in contact with fresh droppings and use other manure for the time being.

4. Can avian flu be transmitted to humans?

Usually, bird flu viruses do not infect humans, but there have been instances of humans contracting it since 1997.

5. How does avian flu spread in birds?

Avian flu spreads when infected birds shed viruses in their saliva, nasal secretions, and feces (droppings). Birds get infected when they come in contact with the contaminated excretions or surfaces.

6. How are humans infected with avian flu?

In most cases, humans are infected either by poultry or contaminated surfaces. In the event of pandemic, it is also possible that a person can catch a virus just by visiting a shop next to one selling chicken.

7. How can bird flu be controlled in poultry?

Culling is the only way to control bird flu in poultry.

8. What are the symptoms of avian flu in humans?

Cough, fever, sore throat, muscle aches, pneumonia, and other complications.

9. Is there any vaccine for humans against avian flu?

There is no vaccine for humans against avian flu. There is no medicine as well.

Elon Musk forms several ‘X Holdings’ companies to fund potential Twitter buyout

3 Mins Read

Thursday’s filing dispelled some doubts, though Musk still has work to do. He and his advisers will spend the coming days vetting potential investors for the equity portion of his offer, according to people familiar with the matter

 Daily Newsletter

KV Prasad Journo follow politics, process in Parliament and US Congress. Former Congressional APSA-Fulbright Fellow

Previous Article

Oil Fluctuates as Traders Assess China’s Vow, Unrest in Libya

Next Article

Shanghai residents turn to NFTs to record COVID lockdown, combat censorship

LIVE TV

today's market

index Price Change
nifty 50 ₹16,986.00 -72.15
sensex ₹1,882.60 +28.30
nifty IT ₹2,206.80 +30.85
nifty bank ₹1,318.95 -14.95
index Price Change
nifty 50 ₹16,986.00 -7.15
sensex ₹1,882.60 +8.30
nifty IT ₹2,206.80 +3.85
nifty bank ₹1,318.95 -1.95
index Price Change
nifty 50 ₹16,986.00 -72.15
sensex ₹1,882.60 +28.30
nifty IT ₹2,206.80 +30.85
nifty bank ₹1,318.95 -14.95
index Price Change
nifty 50 ₹16,986.00 -7.15
sensex ₹1,882.60 +8.30
nifty IT ₹2,206.80 +3.85
nifty bank ₹1,318.95 -1.95
index Price Change
nifty 50 ₹16,986.00 -7.15
sensex ₹1,882.60 +8.30
nifty IT ₹2,206.80 +3.85
nifty bank ₹1,318.95 -1.95

Currency

Company Price Chng %Chng
Dollar-Rupee 73.3500 0.0000 0.00
Euro-Rupee 89.0980 0.0100 0.01
Pound-Rupee 103.6360 -0.0750 -0.07
Rupee-100 Yen 0.6734 -0.0003 -0.05
Quiz
Powered by
Are you a Crypto Head? It’s time to prove it!
10 Questions · 5 Minutes
Start Quiz Now
Win WRX (WazirX token) worth Rs. 1500.
Question 1 of 5

What coins do you think will be valuable over next 3 years?

Answer Anonymously

Should Elon Musk be able to buy Twitter?

 5 Minutes Read

Virus, vaccines and volatility: Stock market takes a wild ride in 2020

KV Prasad Jun 13, 2022, 06:35 AM IST (Published)

 Listen to the Article (6 Minutes)

Summary

Analysts say world stock markets have developed a dangerous addiction to endless money printing by central banks.

From the depths of despair to an adrenaline-pumping ascent, equity investors traversed the whole gamut of emotions in 2020 as a once-in-a-lifetime pandemic followed by equally unprecedented stimulus measures whiplashed global stock markets, upended conventional wisdom and blurred the lines between investing and speculation.

Dalal Street witnessed gut-churning fluctuations, with the BSE Sensex swinging between historic losses and eye-popping gains, sometimes in the same session, and confounded veterans and rookies alike.

No one had anticipated that the Sensex and Nifty would be bludgeoned in late March, or that they will stage a remarkable recovery almost immediately and soar to all-time highs by the end of the year. But, 2020 has been a year full of events outside the realm of imagination.

The year started off on an ominous note for financial markets when on January 3 top Iranian commander Qasem Soleimani was killed in a US drone strike in Iraq, ratcheting up tensions in the Middle East.

The Sensex tumbled more than 900 points over two sessions but resumed its upward march to hit life highs later that month.

Equities largely shrugged off initial reports of a coronavirus outbreak in China, in tandem with the global bourses, and looked ahead to the Budget.

However, the Sensex logged one of its biggest single-day declines on February 1 after the Union Budget failed to live up to market expectations of growth-boosting measures and fiscal discipline.

The real test, alas, was ahead.

From mid-February, world stocks started getting skittish as it became clear that the COVID-19 crisis would not be limited to China.

To add to the woes, Yes Bank was placed under a moratorium in a rare move, triggering a crisis of confidence in the domestic banking sector.

The explosive cocktail of a global market meltdown and domestic troubles proved too much to take for Dalal Street. Four of the biggest single-day declines in the history of BSE Sensex came in March 2020, leaving participants shell-shocked.

Its biggest-ever plunge (in absolute terms) was on March 23, when the benchmark crashed 3,934.72 points or 13.15 per cent.

Astonishingly, March also saw some of the index’s biggest up-moves amid the RBI stepping in with emergency liquidity support.

The Sensex’s largest-ever single-session gain came a little later on April 7, when it zoomed 2,476.26 points as investors wagered on more stimulus measures from the government to battle the economic fallout of the pandemic.

The turbulence on the domestic bourses also mirrored global market turmoil.

The Dow Jones suffered its worst fall, emerging market assets were routed and in a mind-boggling moment, US oil futures turned negative for the first time in history.

For a while, the world stopped making any sense.

With the world economy comatose and governments overwhelmed by a cataclysmic health crisis, the task of propping up the financial markets and restoring investor confidence fell to the global central banks.

“2020 will probably go down in history as a year when global central bankers injected close to USD 11 trillion as stimuli to combat the COVID pandemic, said S Ranganathan, Head of Research at LKP Securities.

The massive money printing by the US Federal Reserve and its peers sparked a breathtaking turnaround in global stock markets.

Never bet against the Fed, as the saying goes.

Flush with funds, foreign portfolio investors (FPIs) poured in billions of dollars into emerging markets, with India topping the chart in Asia.

FPI net inflows into Indian equity markets have crossed Rs 1.5 lakh crore (over USD 20 billion) this year — a lifetime peak.

The Sensex erased its 2020 losses on November 5, while global investors monitored the results of the tightly-contested US elections.

The next booster dose for world markets came over the following few days as companies like Pfizer, Moderna and AstraZeneca began announcing positive results from their COVID-19 vaccine trials.

Human innovation once again triumphed against all odds, setting off a record-shattering relief rally in equities. From November 9 to December 18, the Sensex hit fresh record highs in 22 out of the 29 sessions.

For the calendar year (till December 24), the Sensex has gained 13.86 per cent, while the Nifty has delivered returns of 12.99 per cent.

Compared to the March lows, both the indices are up by a hefty 80 per cent.

Benchmarks had another engine propelling them higher this year  Reliance Industries (RIL), which became the first Indian company to reach a market capitalisation of Rs 15 lakh crore (USD 200 billion) in September.

Beginning April, the Mukesh Ambani-led conglomerate announced a slew of deals to sell minority stakes in its telecom and retail arms to marquee investors like Facebook, Google, Silver Lake, KKR, Mubadala, and Public Investment Fund of Saudi Arabia.

The company has raised around USD 25 billion so far this year as it seeks to ramp up its consumer-facing businesses.

For a good part of the year, RIL almost single-handedly drove the domestic benchmarks higher in the absence of any buying triggers.

The COVID-19 crisis also forced investors to take a relook at their sectoral allocations.

“From the lows, markets started stabilising and pandemic sectors like FMCG, IT, pharma and chemicals benefitted. As the economy further opened up, growth and cyclical sectors reversed positively,” said Vinod Nair, Head of Research at Geojit Financial Services.

However, while stocks seem to have found their animal spirits back, there are also some murmurs of discontent.

Analysts say world stock markets have developed a dangerous addiction to endless money printing by central banks, and show withdrawal symptoms of a junkie at the slightest indication of a moderation in monetary stimulus.

Back home too, around half of the government’s Rs 20.97 lakh crore economic stimulus package comprised RBI’s liquidity measures.

This glut of global liquidity has pushed markets so far ahead of economic fundamentals that some are beginning to question whether the real economy matters in equity investing at all.

For example, no one would be able to tell looking at the Sensex chart that the Indian economy shrank 23.9 per cent in the first three months of FY21, and 7.5 per cent the next quarter.

Globally too, markets have been on a manic upswing even as millions have lost their jobs, small businesses are battling for survival and entire industries have been decimated.

While the real economy has been ravaged by the pandemic, most financial market indicators are ruling at stratospheric levels.

The BSE Sensex is currently trading at a price-to-earnings (PE) ratio of 32.89, the highest on record.

To put it differently, investors are paying Rs 32.89 for every rupee of future earnings of the 30 Sensex firms, compared to the previous 20-year average of around Rs 19.

Global market capitalisation — the value of all the listed stocks in the world  topped $100 trillion for the first time ever in December.

And in a classic sign of market mania, there’s a rush of first-time investors eager to make a quick buck.

A record 68 lakh new dematerialised (or demat) accounts were opened in India between April and October 2020, compared to nearly 49 lakh in the entire FY20, which was the highest in a decade.

Experts attribute this trend to factors like increased time at home due to the lockdown, efforts to make up for lost jobs or incomes, and also FOMO, or the fear of missing out on this rally.

This is also reflected in the growing popularity of discount broking apps like Zerodha and Upstox, which have dislodged traditional broking houses in terms of active clients.

Like the Robinhood app in the US, such platforms have attracted the tech-savvy crowd with their slick interface and mobile-first approach which has ‘gamified’ the once-stodgy field of stock market investing.

With Fed and FOMO playing in tandem, many questioned technicalities like PE and PB ratios. But, some analysts also maintain that 2020 was an outlier in terms of corporate earnings and hence valuation metrics like PE ratios this year are not strictly comparable to historical averages.

However, even they agree that every segment of the economy would have to stage a synchronous and sensational comeback to catch up with the market projections.

And if that comes to pass, 2021 would be an even more incredible year for the bourses.

Elon Musk forms several ‘X Holdings’ companies to fund potential Twitter buyout

3 Mins Read

Thursday’s filing dispelled some doubts, though Musk still has work to do. He and his advisers will spend the coming days vetting potential investors for the equity portion of his offer, according to people familiar with the matter

 Daily Newsletter

KV Prasad Journo follow politics, process in Parliament and US Congress. Former Congressional APSA-Fulbright Fellow

Previous Article

Oil Fluctuates as Traders Assess China’s Vow, Unrest in Libya

Next Article

Shanghai residents turn to NFTs to record COVID lockdown, combat censorship

LIVE TV

today's market

index Price Change
nifty 50 ₹16,986.00 -72.15
sensex ₹1,882.60 +28.30
nifty IT ₹2,206.80 +30.85
nifty bank ₹1,318.95 -14.95
index Price Change
nifty 50 ₹16,986.00 -7.15
sensex ₹1,882.60 +8.30
nifty IT ₹2,206.80 +3.85
nifty bank ₹1,318.95 -1.95
index Price Change
nifty 50 ₹16,986.00 -72.15
sensex ₹1,882.60 +28.30
nifty IT ₹2,206.80 +30.85
nifty bank ₹1,318.95 -14.95
index Price Change
nifty 50 ₹16,986.00 -7.15
sensex ₹1,882.60 +8.30
nifty IT ₹2,206.80 +3.85
nifty bank ₹1,318.95 -1.95
index Price Change
nifty 50 ₹16,986.00 -7.15
sensex ₹1,882.60 +8.30
nifty IT ₹2,206.80 +3.85
nifty bank ₹1,318.95 -1.95

Currency

Company Price Chng %Chng
Dollar-Rupee 73.3500 0.0000 0.00
Euro-Rupee 89.0980 0.0100 0.01
Pound-Rupee 103.6360 -0.0750 -0.07
Rupee-100 Yen 0.6734 -0.0003 -0.05
Quiz
Powered by
Are you a Crypto Head? It’s time to prove it!
10 Questions · 5 Minutes
Start Quiz Now
Win WRX (WazirX token) worth Rs. 1500.
Question 1 of 5

What coins do you think will be valuable over next 3 years?

Answer Anonymously

Should Elon Musk be able to buy Twitter?

 5 Minutes Read

Extensive testing, early diagnosis and early isolation needed to beat COVID-19, says Dr B Chandra Mohan

KV Prasad Jun 13, 2022, 06:35 AM IST (Published)

 Listen to the Article (6 Minutes)

Summary

India’s active COVID-19 cases have been declining every day and have fallen sharply by 3.2 lakh cases in the last 24 days. Today’s decline of 27,800 active cases has been the biggest single-day decline so far.

India’s active COVID-19 cases have been declining every day and have fallen sharply by 3.2 lakh cases in the last 24 days. Today’s decline of 27,800 active cases has been the biggest single-day decline so far.

Doctor Jayaprakash Muliyil, India’s top epidemiologists and Chairman of the Scientific Advisory Committee of the National Institute of Epidemiology told CNBC-TV18 in a recent interview that most regions of the country were showing signs of herd immunity and that explained the drop in the number of active COVID-19 cases.

At present, India stands at 86 deaths per million cases versus 697 deaths per million patients in the US, and 739 deaths per million patients in Brazil.

To find out if the drop in active cases would continue through the festive season and what states are doing to curb the spread of the infection, Archana Shukla spoke to the Head of COVID-19 National Supermodel Panel M Vidyasagar, Chhattisgarh Health Minister TS Singh Deo and Principal Secretary in the Tamil Nadu government Dr B Chandra Mohan.

Vidyasagar said, “Nobody knows what would happen when the cold weather approaches and whether the virus would spread faster. Then, we would have rework our weekly recalibrations. The US and Europe are much more worried about this because as temperatures drop drastically as compared to India.”

While giving his assessment on the ground situation in Tamil Nadu, Dr Chandra Mohan said, “For the first time in the last 101 days we have seen a dip in the number of cases not only at an all-India level, but in Tamil Nadu as well. If we can identify [patients] through early testing, diagnosis and isolate them, then the basic reproductive number or the ‘R naught’ or R0 will actually decline. In Tamil Nadu R naught is between 1.52-1.54.”

He added, “This decline in the number of cases is a cumulative effect of all the efforts that have gone into the field in Tamil Nadu.”

To know more, watch the video.

Elon Musk forms several ‘X Holdings’ companies to fund potential Twitter buyout

3 Mins Read

Thursday’s filing dispelled some doubts, though Musk still has work to do. He and his advisers will spend the coming days vetting potential investors for the equity portion of his offer, according to people familiar with the matter

 Daily Newsletter

KV Prasad Journo follow politics, process in Parliament and US Congress. Former Congressional APSA-Fulbright Fellow

Previous Article

Oil Fluctuates as Traders Assess China’s Vow, Unrest in Libya

Next Article

Shanghai residents turn to NFTs to record COVID lockdown, combat censorship

LIVE TV

today's market

index Price Change
nifty 50 ₹16,986.00 -72.15
sensex ₹1,882.60 +28.30
nifty IT ₹2,206.80 +30.85
nifty bank ₹1,318.95 -14.95
index Price Change
nifty 50 ₹16,986.00 -7.15
sensex ₹1,882.60 +8.30
nifty IT ₹2,206.80 +3.85
nifty bank ₹1,318.95 -1.95
index Price Change
nifty 50 ₹16,986.00 -72.15
sensex ₹1,882.60 +28.30
nifty IT ₹2,206.80 +30.85
nifty bank ₹1,318.95 -14.95
index Price Change
nifty 50 ₹16,986.00 -7.15
sensex ₹1,882.60 +8.30
nifty IT ₹2,206.80 +3.85
nifty bank ₹1,318.95 -1.95
index Price Change
nifty 50 ₹16,986.00 -7.15
sensex ₹1,882.60 +8.30
nifty IT ₹2,206.80 +3.85
nifty bank ₹1,318.95 -1.95

Currency

Company Price Chng %Chng
Dollar-Rupee 73.3500 0.0000 0.00
Euro-Rupee 89.0980 0.0100 0.01
Pound-Rupee 103.6360 -0.0750 -0.07
Rupee-100 Yen 0.6734 -0.0003 -0.05
Quiz
Powered by
Are you a Crypto Head? It’s time to prove it!
10 Questions · 5 Minutes
Start Quiz Now
Win WRX (WazirX token) worth Rs. 1500.
Question 1 of 5

What coins do you think will be valuable over next 3 years?

Answer Anonymously

Should Elon Musk be able to buy Twitter?

 5 Minutes Read

Trial drug shows promise as potential treatment for COVID-19: Study

KV Prasad Jun 13, 2022, 06:35 AM IST (Published)

 Listen to the Article (6 Minutes)

Summary

Scientists have found a trial drug that effectively blocks the cellular door SARS-CoV-2 uses to infect its hosts, an advance that they say may provide a potential treatment for the novel coronavirus.

Scientists have found a trial drug that effectively blocks the cellular door SARS-CoV-2 uses to infect its hosts, an advance that they say may provide a potential treatment for the novel coronavirus.

The study, published in the journal Cell, provides new insights into key aspects of SARS-CoV-2, the virus that causes COVID-19. It also provides details about the interactions of the virus on a cellular level, as well as how it can infect blood vessels and kidneys.

“We are hopeful our results have implications for the development of a novel drug for the treatment of this unprecedented pandemic,” said Josef Penninger, from the University of British Columbia in Canada.

The researchers said ACE2 — a protein on the surface of the cell membrane — is now at centre-stage in this outbreak as the key receptor for the spike glycoprotein of SARS-CoV-2.

In earlier work, Penninger and colleagues at the University of Toronto and the Institute of Molecular Biology in Austria found that in living organisms, ACE2 is the key receptor for SARS, the viral respiratory illness recognised as a global threat in 2003.

The absence of a clinically proven antiviral therapy or a treatment specifically targeting the critical SARS-CoV-2 receptor ACE2 on a molecular level has meant an empty arsenal for health care providers struggling to treat severe cases of COVID-19, the researchers said.

“Our new study provides very much needed direct evidence that a drug — called APN01 (human recombinant soluble angiotensin-converting enzyme 2 — hrsACE2) — soon to be tested in clinical trials by the European biotech company Apeiron Biologics, is useful as an antiviral therapy for COVID-19,” said Art Slutsky, a professor at the University of Toronto.

In cell cultures, hrsACE2 inhibited the coronavirus load by a factor of 1,000-5,000, the researchers found. In engineered replicas of human blood vessel and kidneys — organoids grown from human stem cells — the researchers demonstrated that the virus can directly infect and duplicate itself in these tissues.

This provides important information on the development of the disease and the fact that severe cases of COVID-19 present with multi-organ failure and evidence of cardiovascular damage, they said. The team found that clinical grade hrsACE2 also reduced the SARS-CoV-2 infection in these engineered human tissues.

“Using organoids allows us to test in a very agile way treatments that are already being used for other diseases, or that are close to being validated,” said Nuria Montserrat, a professor at the Institute for Bioengineering of Catalonia in Spain.

“The virus causing COVID-19 is a close sibling to the first SARS virus,” Penninger added. Previous work helped the researchers to rapidly identify ACE2 as the entry gate for SARS-CoV-2, which explains a lot about the disease.

In the latest study, they found that a soluble form of ACE2 that catches the virus away, could be a very rational therapy that specifically targets the gate the virus must take to infect people.

Elon Musk forms several ‘X Holdings’ companies to fund potential Twitter buyout

3 Mins Read

Thursday’s filing dispelled some doubts, though Musk still has work to do. He and his advisers will spend the coming days vetting potential investors for the equity portion of his offer, according to people familiar with the matter

 Daily Newsletter

KV Prasad Journo follow politics, process in Parliament and US Congress. Former Congressional APSA-Fulbright Fellow

Previous Article

Oil Fluctuates as Traders Assess China’s Vow, Unrest in Libya

Next Article

Shanghai residents turn to NFTs to record COVID lockdown, combat censorship

LIVE TV

today's market

index Price Change
nifty 50 ₹16,986.00 -72.15
sensex ₹1,882.60 +28.30
nifty IT ₹2,206.80 +30.85
nifty bank ₹1,318.95 -14.95
index Price Change
nifty 50 ₹16,986.00 -7.15
sensex ₹1,882.60 +8.30
nifty IT ₹2,206.80 +3.85
nifty bank ₹1,318.95 -1.95
index Price Change
nifty 50 ₹16,986.00 -72.15
sensex ₹1,882.60 +28.30
nifty IT ₹2,206.80 +30.85
nifty bank ₹1,318.95 -14.95
index Price Change
nifty 50 ₹16,986.00 -7.15
sensex ₹1,882.60 +8.30
nifty IT ₹2,206.80 +3.85
nifty bank ₹1,318.95 -1.95
index Price Change
nifty 50 ₹16,986.00 -7.15
sensex ₹1,882.60 +8.30
nifty IT ₹2,206.80 +3.85
nifty bank ₹1,318.95 -1.95

Currency

Company Price Chng %Chng
Dollar-Rupee 73.3500 0.0000 0.00
Euro-Rupee 89.0980 0.0100 0.01
Pound-Rupee 103.6360 -0.0750 -0.07
Rupee-100 Yen 0.6734 -0.0003 -0.05
Quiz
Powered by
Are you a Crypto Head? It’s time to prove it!
10 Questions · 5 Minutes
Start Quiz Now
Win WRX (WazirX token) worth Rs. 1500.
Question 1 of 5

What coins do you think will be valuable over next 3 years?

Answer Anonymously

Should Elon Musk be able to buy Twitter?